Synthesis, stability, biochemical and pharmacokinetic properties of a new potent and selective 4-oxo-β-lactam inhibitor of human leukocyte elastase

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 26, Issue 2, 2011, Pages 169-175

  Mulchande, Jalmira ^a   Simões, Sandra I ^a   Gaspar, Maria M ^a   Eleutéio, Carla V ^a   Oliveira, Rudi ^a   Cruz, Maria E M ^a   Moreira, Rui ^a   Iley, Jim ^b  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b OPEN UNIVERSITY   (United Kingdom)

Author keywords

biodistribution; human leukocyte elastase; human plasma; proteinase 3; Slow tight binding; stability

Indexed keywords

3,3 DIETHYL 1 [4 (PHENYLSULPHONYLMETHYL)PHENYL]AZETIDINE 2,4 DIONE; BETA LACTAM; CATHEPSIN G; LEUKOCYTE ELASTASE; LEUKOCYTE ELASTASE INHIBITOR; MYELOBLASTIN; UNCLASSIFIED DRUG;

ACYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BLOOD; CONTROLLED STUDY; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LUNG; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PH; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN;

ANIMALS; BETA-LACTAMS; DRUG STABILITY; ENZYME INHIBITORS; HUMANS; INFUSIONS, PARENTERAL; LEUKOCYTE ELASTASE; MALE; MICE; MOLECULAR STRUCTURE;

MUS;

EID: 79952059337     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2010.486794     Document Type: Article

References (32)

1. Bode W, Meyer E, Powers JC. Human-leukocyte and porcine pancreatic elastase-X-ray crystal-structures, mechanism, substrate-specifcity, and mechanism-based inhibitors. Biochemistry 1989;28:1951-1963. (Pubitemid 19084420)
2. Barnes PJ. Chronic obstructive pulmonary disease: A growing but neglected global epidemic. PLos Med 2007;4:779-780.
3. Chua F, Laurent GJ. Neutrophil elastase: mediator of extracellular matrix destruction and accumulation. Proc Am Torac Soc 2006;3:424-427. (Pubitemid 44033357)
4. Lee WL, P. Downey G. Leukocyte elastase physiological functions and role in acute lung injury. Am J Respir Crit Care Med 2001;164:896-904. (Pubitemid 32881931)
5. Moraes TJ, Chow CW, Downey GP. Proteases and lung injury. Crit Care Med 2002;13:S189-S194 (Pubitemid 36458166)
6. World Health Report 2000 statistical annex. World Health Organization. 2000 [cited January 2009]; Available from: http://www.who.int/whr/2000/en/ statistics.htm.
7. Roughley PJ, Barrett AJ. Te degradation of cartilage proteoglycans by tissue proteinases proteoglycan structure and its susceptibility to proteolysis. Biochem J 1977;167:629-637. (Pubitemid 8240979)
8. Pham CTN. Neutrophil serine proteases: specifc regulators of infammation. Nature Rev Immunol 2006;6:541-550. (Pubitemid 43980526)
9. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Te Lancet 2004;364:985-996. (Pubitemid 39208462)
10. Abbenante G, Fairlie DP. Protease inhibitors in the clinic Med Chem 2005;1:71-104.
11. Malhotra S, Man SFP, Sin DD. Emerging drugs for the treatment of chronic obstructive pulmonary disease. Exp Opinion Emerging Drugs 2006;11:275-291. (Pubitemid 43723309)
12. Ohbayashi H. Current synthetic inhibitors of human neutrophil elastase. Exp Opin Ter Pat 2002;12:65-84. (Pubitemid 34048610)
13. Mulchande J, Guedes RC, Tsang WY, Page MI, Moreira R, Iley J. Azetidine-2,4-diones (4-Oxo-b-lactams) as scafolds for designing elastase inhibitors. J Med Chem 2008;51:1783-1790. (Pubitemid 351438860)
14. Mulchande J, Oliveira R, Carrasco M, Gouveia L, Guedes RC, Iley J, Moreira R. Azetidine-2,4-diones (4-oxo-b-lactams) are potent and selective inhibitors of human leukocyte elastase J Med Chem 2010;53:241-253.
15. Log P value calculated using molinspiration. [cited November 2009]; Available from: http://www.molinspiration.com
16. Groutas WC, Epp JB, Venkataraman R, Kuang RZ, Truong TM, McClenahan JJ, Prakash O. Design, synthesis, and in vitro inhibitory activity toward human leukocyte elastase, cathepsin G, and proteinase 3 of saccharin-derived sulfones and congeners. Bioorg Med Chem 1996;4:1393-1400. (Pubitemid 26319990)
17. Groutas WC, Kuang R, Venkataraman R, Epp JB, Ruan S, Prakash O. Structure-based design of a general class of mechanism-based inhibitors of the serine proteinases employing a novel amino acid-derived heterocyclic scafold. Biochemistry 1997;36:4739-4750. (Pubitemid 27180954)
18. Groutas WC, Kuang RZ, Ruan SM, Epp JB, Venkataraman R, Truong TM. Potent and specifc inhibition of human leukocyte elastase, cathepsin g and proteinase 3 by sulfone derivatives employing the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scafold. Bioorg Med Chem 1998;6:661-671. (Pubitemid 28287268)
19. He S, Kuang RZ, Venkataraman R, Tu J, Truong TM, Chan HK, Groutas WC. Potent inhibition of serine proteases by heterocyclic sulfde derivatives of 1,2,5-thiadiazolidin-3-one 1,1 dioxide. Bioorg Med Chem 2000;8:1713-1717. (Pubitemid 30427236)
20. Li Y Yang Q, Dou D, Alliston KR, Groutas WC. Inactivation of human neutrophil elastase by 1,2,5-thiadiazolidin-3-one 1,1 dioxide-based sulfonamides. Bioorg Med Chem 2008;16:692-698. (Pubitemid 351163069)
21. Li Y Dou DF, He GJ, Lushington GH, Groutas WC. Mechanism-based inhibitors of serine proteases with high selectivity through optimization of S ' subsite binding. Bioorg Med Chem 2009;17:3536-3542.
22. Mulchande J, Martins L, Moreira R, Archer M, Oliveira TF, Iley J. Te efciency of C-4 substituents in activating the b-lactam scafold towards serine proteases and hydroxide ion. Org Biomol Chem 2007;5: 2617-2626. (Pubitemid 47192315)
23. Copeland RA. Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists New Jersey: John Wiley and Son, 2005. pp. 141-177.
24. Gaspar MM, Cruz A, Penha AE, Reymao J, Sousa AC, Eleuterio CV Domingues SA, Fraga AG, Filho AL. Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. Int J Antimicrob Agents 2008;31: 37-45. (Pubitemid 350245738)
25. Morrison JF, Walsh CT. Te behavior and signifcance of slow-binding enzyme inhibitors. Adv Enzymol 1988;61:201-301.
26. Gutschow M, Neumann U. Novel thieno[2,3-d][1,3]oxazin-4-ones as inhibitors of human leukocyte elastase. J Med Chem 1998;41: 1729-1740. (Pubitemid 28221967)
27. Doherty JB, Ashe BM, Argenbright LW, Barker PL, Bonney RJ, Chandler GO, Dahlgren ME, Dorn CP, Finke PE. Cephalosporin antibiotics can be modifed to inhibit human-leukocyte elastase. Nature 1986;322:192-194. (Pubitemid 16005462)
28. Finke PE, Dorn CP, Kissinger AL, Shah SK, Ball RG, Chabin R, Davie P, Dellea PS, Doherty JB. Orally-Active, Intracellular Inhibitors of Human-Leukocyte Elastase (Hle). 22nd National Meeting of the American Chemical Society; 1995 Aug; Chicago; 1995: 83-MEDI.
29. Ilies MA, Scozzafava A, Supuran CT. Terapeutic applications of serine protease inhibitors. Expert Opin Ter Pat 2002;12:1181-1214. (Pubitemid 34919200)
30. Korkmaz B, Moreau T, Gauthier F. Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions. Biochimie 2008;90:227-242. (Pubitemid 351187763)
31. Alpegiani M, Bissolino P, Corigli R, Delnero S, Perrone E, Rizzo V Sacchi N, Cassinelli G, Franceschi G, Baici A.Cephem sulfones as inactivators of human-leukocyte elastase.5. 7-Alpha-methoxy-1,1-dioxocephem-4-ketone and 7-alpha-chloro-1,1-dioxocephem-4-ketone. J Med Chem 1994;37:4003-4019.
32. Vincent SH, Painter SK, LuferAtlas D, Karanam BV McGowan E, Ciofe C, Doss G, Chiu SHL.Orally active inhibitors of human leukocyte elastase.2. Disposition of L-694,458 in rats and rhesus monkeys. Drug Metab Dispos 1997;25:932-939. (Pubitemid 27357691)